Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 29 Carcinoma, Renal Cell 26 Endometrial Neoplasms 13 Melanoma 10 Neoplasms 8 Uterine Cervical Neoplasms 7 Cholangiocarcinoma 7 Biliary Tract Neoplasms 7 Liver Neoplasms 6 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Neuroendocrine Tumors 5 Triple Negative Breast Neoplasms 4 Thyroid Neoplasms 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Esophageal Squamous Cell Carcinoma 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Recurrence 3 Kidney Neoplasms 3 Esophageal Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Carcinoma, Adenoid Cystic 3 Breast Neoplasms 3 Brain Neoplasms 3 Adenocarcinoma 3 Vulvar Neoplasms 2

Interventions

pembrolizumab 4 Cyclophosphamide 4 Radiotherapy 3 Cisplatin 3 fludarabine 2 Doxorubicin 2 Carboplatin 2 zimberelimab 1 olaparib 1 lenvatinib 1 envafolimab 1 avelumab 1 Thymectomy 1 Taxes 1 Sunitinib 1 Robotic Surgical Procedures 1 Ramucirumab 1 Radiotherapy, Adjuvant 1 Paclitaxel 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Etoposide 1 Drug Therapy 1 Chemoradiotherapy 1 Cetuximab 1 AP 1903 reagent 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × lenvatinib × 1 year × Clear all

NCT04710628 2026-02-19

PECATI

MedSIR

Phase 2 Completed

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡